ArticleCost effectiveness and resource allocation : C/E2025

Cost-effectiveness analysis of second intravenous immunoglobulin infusion versus infliximab for treating IVIG-resistant Kawasaki disease patients.

Jada M Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.